Literature DB >> 15028972

Collagenous colitis: implications for the role of vascular endothelial growth factor in repair mechanisms.

Thomas Griga1, Andreas Tromm, Wolff Schmiegel, Okka Pfisterer, Klaus-M Müller, Frank Brasch.   

Abstract

OBJECTIVES: Collagenous colitis is a chronic inflammatory bowel disease with a band-like subepithelial deposition of immature extracellular matrix. Because the extracellular matrix deposition is potentially reversible, an imbalance between fibrogenesis and fibrolysis with reduced matrix degradation has been suspected. Vascular endothelial growth factor plays a central role in extracellular matrix degradation. Therefore, we investigated the expression of vascular endothelial growth factor in the colonic mucosa of patients with collagenous colitis before and after long-term treatment with oral budesonide.
METHOD: A quantitative immunohistochemical method was used to measure the amount of immunoreactive vascular endothelial growth factor, tenascin and leucocyte common antigen within the epithelium and the lamina propria of colonic biopsies by area morphometry.
RESULTS: Strong immunostaining for vascular endothelial growth factor within the epithelium and the lamina propria, and for tenascin, was seen in patients with collagenous colitis compared with normal controls. The enhanced immunostaining for vascular endothelial growth factor within the lamina propria was accompanied by the accumulation of leucocytes, detected by staining for leucocyte common antigen. After long-term treatment with oral budesonide, the amount of immunostaining for leucocyte-derived vascular endothelial growth factor within the lamina propria decreased significantly to normal levels. In contrast, staining for vascular endothelial growth factor within the epithelium remained significantly increased.
CONCLUSIONS: Our data suggest an important role of vascular endothelial growth factor in counteracting the local imbalance of fibrogenesis and fibrolysis, leading to an accumulation of immature subepithelial matrix in collagenous colitis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15028972     DOI: 10.1097/00042737-200404000-00005

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  14 in total

1.  Noninfectious colitides: collagenous colitis, lymphocytic colitis, diversion colitis, and chemically induced colitis.

Authors:  Amy J Thorsen
Journal:  Clin Colon Rectal Surg       Date:  2007-02

2.  PDGF and TGF-β promote tenascin-C expression in subepithelial myofibroblasts and contribute to intestinal mucosal protection in mice.

Authors:  M S Islam; M Kusakabe; K Horiguchi; S Iino; T Nakamura; K Iwanaga; H Hashimoto; S Matsumoto; T Murata; M Hori; H Ozaki
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

Review 3.  Diagnosis and Management of Microscopic Colitis.

Authors:  Darrell S Pardi
Journal:  Am J Gastroenterol       Date:  2016-11-29       Impact factor: 10.864

4.  Microscopic Colitis: A Review of Collagenous and Lymphocytic Colitis.

Authors:  Karen Boland; Geoffrey C Nguyen
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-11

5.  Steroids reduce local inflammatory mediator secretion and mucosal permeability in collagenous colitis patients.

Authors:  Yesuf Taha; Yngve Raab; Marie Carlson; Anders Larsson; Mikael Lördal; Lars Lööf; Magnus Thörn
Journal:  World J Gastroenterol       Date:  2006-11-21       Impact factor: 5.742

Review 6.  Diagnosis and Management of Microscopic Colitis in Pediatric Patients.

Authors:  Salina Khushal; Maria Oliva-Hemker
Journal:  Paediatr Drugs       Date:  2022-05-02       Impact factor: 3.022

Review 7.  Diagnosis and management of microscopic colitis.

Authors:  Curt Tysk; Johan Bohr; Nils Nyhlin; Anna Wickbom; Sune Eriksson
Journal:  World J Gastroenterol       Date:  2008-12-28       Impact factor: 5.742

Review 8.  Stem cells as a potential future treatment of pediatric intestinal disorders.

Authors:  Troy A Markel; Paul R Crisostomo; Tim Lahm; Nathan M Novotny; Frederick J Rescorla; Joseph Tector; Daniel R Meldrum
Journal:  J Pediatr Surg       Date:  2008-11       Impact factor: 2.545

9.  Enhancing apoptotic cell clearance mitigates bacterial translocation and promotes tissue repair after gut ischemia-reperfusion injury.

Authors:  Rongqian Wu; Weifeng Dong; Zhimin Wang; Asha Jacob; Tianpen Cui; Ping Wang
Journal:  Int J Mol Med       Date:  2012-06-26       Impact factor: 4.101

10.  VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy.

Authors:  A H R Varey; E S Rennel; Y Qiu; H S Bevan; R M Perrin; S Raffy; A R Dixon; C Paraskeva; O Zaccheo; A B Hassan; S J Harper; D O Bates
Journal:  Br J Cancer       Date:  2008-03-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.